Correction to: Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial

Detalles Bibliográficos
Autor principal: Seino, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479026/
https://www.ncbi.nlm.nih.gov/pubmed/34515989
http://dx.doi.org/10.1007/s13300-021-01123-w
_version_ 1784576160225558528
author Seino, Hiroaki
author_facet Seino, Hiroaki
author_sort Seino, Hiroaki
collection PubMed
description
format Online
Article
Text
id pubmed-8479026
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-84790262021-10-08 Correction to: Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial Seino, Hiroaki Diabetes Ther Correction Springer Healthcare 2021-09-13 2021-10 /pmc/articles/PMC8479026/ /pubmed/34515989 http://dx.doi.org/10.1007/s13300-021-01123-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Correction
Seino, Hiroaki
Correction to: Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial
title Correction to: Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial
title_full Correction to: Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial
title_fullStr Correction to: Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial
title_full_unstemmed Correction to: Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial
title_short Correction to: Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial
title_sort correction to: efficacy and safety of luseogliflozin in patients with type 2 diabetes complicated by hepatic dysfunction: a single-site, single-arm, open-label, exploratory trial
topic Correction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479026/
https://www.ncbi.nlm.nih.gov/pubmed/34515989
http://dx.doi.org/10.1007/s13300-021-01123-w
work_keys_str_mv AT seinohiroaki correctiontoefficacyandsafetyofluseogliflozininpatientswithtype2diabetescomplicatedbyhepaticdysfunctionasinglesitesinglearmopenlabelexploratorytrial

Ejemplares similares